United States · 
Who invested in Crossbow Therapeutics?
Crossbow Therapeutics's investors include Polaris Partners and Eli Lilly.
2026
$30MVenture$77MSeries BUnited States · Series B startup
Who invested in Crossbow Therapeutics
2 rounds we have observed, with the 2 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Raised 8 months ago
Funding summaryUpdated 26 Oct 2026
$107Mraised across 2 rounds since 2025, from 2 sources
$30MVenture$77MSeries B
- Latest round
- Series B, $77MMar 2026
- Step-upi
- 2.5×
- Investors
- 2
The funding story
Each circle is a round, placed by date and sized by amount. The line above is the running total.
- First round
- Venture, $30M Sept 2025
- Biggest round
- $77M Series B · Mar 2026
- Between rounds
- 6 months from the last two
The rounds
- Mar 2026
- Sept 2025
Who was in which round
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Everyone who backed them
Missing a round, or an investor who was in one? Tell us.
Quick answers about Crossbow Therapeutics
How much has Crossbow Therapeutics raised?
Crossbow Therapeutics has raised $107M across 2 rounds since 2025.
When did Crossbow Therapeutics last raise?
Crossbow Therapeutics's most recent round was a Series B of $77M in Mar 2026.
What was Crossbow Therapeutics's biggest round?
Its most recent round, $77M in Mar 2026, is also its largest on record.
Who backed Crossbow Therapeutics first?
Crossbow Therapeutics's first round on record, in Sept 2025, was backed by Polaris Partners and Eli Lilly.
What stage is Crossbow Therapeutics at?
Crossbow Therapeutics's latest named round is a Series B, in Mar 2026.
Where is Crossbow Therapeutics based?
Crossbow Therapeutics is based in the United States.
Companies like Crossbow Therapeutics
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.